Molecular Oncology
Volume 4, Issue 1 , Pages 19-37, February 2010

Targeted Therapies: The Rare Cancer Paradigm

  • Marco A. Pierotti

      Affiliations

    • Scientific Directorate, Fondazione IRCCS – Istituto Nazionale dei Tumori Milano, Via Venezian 1, 20133 Milan, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 02 2390 2300.
    • ,
  • Tiziana Negri

      Affiliations

    • Laboratory of Experimental Molecular Pathology, Fondazione IRCCS – Istituto Nazionale dei Tumori Milano, Via Venezian 1, 20133 Milan, Italy
    • ,
  • Elena Tamborini

      Affiliations

    • Laboratory of Experimental Molecular Pathology, Fondazione IRCCS – Istituto Nazionale dei Tumori Milano, Via Venezian 1, 20133 Milan, Italy
    • ,
  • Federica Perrone

      Affiliations

    • Laboratory of Experimental Molecular Pathology, Fondazione IRCCS – Istituto Nazionale dei Tumori Milano, Via Venezian 1, 20133 Milan, Italy
    • ,
  • Sabrina Pricl

      Affiliations

    • Molecular Simulation Engineering Laboratory, DICAMP, University of Trieste, Piazzale Europa 1, 34127 Trieste, Italy
    • ,
  • Silvana Pilotti

      Affiliations

    • Laboratory of Experimental Molecular Pathology, Fondazione IRCCS – Istituto Nazionale dei Tumori Milano, Via Venezian 1, 20133 Milan, Italy

Received 15 October 2009; accepted 21 October 2009. published online 05 November 2009.

Abstract 

This review analyzes the state of the art of targeted therapies for several tumors, starting from the paradigmatic example of Imatinib treatment in chronic myelogenous leukemia (CML). We discuss how rare tumors can be models for various mechanisms of receptor tyrosine kinase (RTK) activation, and provide the opportunity to develop new therapies also for more common cancer types. We discuss the activation of the downstream RTK effectors as further targets for therapies in colorectal cancer. Finally, we highlight how a novel multidimensional approach which adds an in silico dimension to the in vitro and in vivo approach, can predict clinical results.

Keywords: Targeted therapies, Imatinib treatment, Chronic myelogenous leukemia, Activation of downstream RTK effectors

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1574-7891(09)00131-8

doi:10.1016/j.molonc.2009.10.003

Molecular Oncology
Volume 4, Issue 1 , Pages 19-37, February 2010

Article Tools

* Image Usage & Resolution